{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:59:29Z","timestamp":1793951969998,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.arr.2023.102112","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T02:23:00Z","timestamp":1698459780000},"page":"102112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["The proteinopenia hypothesis: Loss of A\u03b242 and the onset of Alzheimer\u2019s Disease"],"prefix":"10.1016","volume":"92","author":[{"given":"Alberto J.","family":"Espay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Herrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper P.","family":"Kepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1650-242X","authenticated-orcid":false,"given":"Timothy","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2023.102112_bib1","doi-asserted-by":"crossref","first-page":"n156","DOI":"10.1136\/bmj.n156","article-title":"Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis","volume":"372","author":"Ackley","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.arr.2023.102112_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archneur.58.3.373","article-title":"Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice","volume":"58","author":"Andreasen","year":"2001","journal-title":"Arch. Neurol."},{"issue":"8","key":"10.1016\/j.arr.2023.102112_bib3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jalz.2018.03.005","article-title":"Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease","volume":"14","author":"Brookmeyer","year":"2018","journal-title":"Alzheimer's Dement.: J. Alzheimer's Assoc."},{"issue":"11","key":"10.1016\/j.arr.2023.102112_bib4","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/mp.2013.194","article-title":"APOE2 enhances neuroprotection against Alzheimer's disease through multiple molecular mechanisms","volume":"19","author":"Conejero-Goldberg","year":"2014","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.arr.2023.102112_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2023.102112_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109002","article-title":"Exogenous A\u03b21-42 monomers improve synaptic and cognitive function in Alzheimer's disease model mice","volume":"209","author":"Duan","year":"2022","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.arr.2023.102112_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.arr.2023.102112_bib8","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal alzheimer's disease","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2023.102112_bib9","doi-asserted-by":"crossref","DOI":"10.3233\/JAD-210415","article-title":"Soluble amyloid-\u03b2 consumption in alzheimer's disease","author":"Espay","year":"2021","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.arr.2023.102112_bib10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.arr.2023.102112_bib11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(21)00139-3","article-title":"Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study","volume":"20","author":"Fagan","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2023.102112_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106631","article-title":"Role of monomeric amyloid-\u03b2 in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies","volume":"187","author":"Imbimbo","year":"2023","journal-title":"Pharmcol. Res."},{"issue":"10","key":"10.1016\/j.arr.2023.102112_bib13","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamaneurol.2019.1971","article-title":"Prevalence of biologically vs clinically defined alzheimer spectrum entities using the national institute on aging-alzheimer's association research framework","volume":"76","author":"Jack","year":"2019","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.arr.2023.102112_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00401-020-02196-w","article-title":"The physiological roles of tau and A\u03b2: implications for Alzheimer's disease pathology and therapeutics","volume":"140","author":"Kent","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"14","key":"10.1016\/j.arr.2023.102112_bib15","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.arr.2023.102112_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000358800","article-title":"Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid","volume":"14","author":"Portelius","year":"2014","journal-title":"Neurodegener. Dis."},{"issue":"189","key":"10.1016\/j.arr.2023.102112_bib17","doi-asserted-by":"crossref","first-page":"189ra77","DOI":"10.1126\/scitranslmed.3005615","article-title":"Increased in vivo amyloid-\u03b242 production, exchange, and loss in presenilin mutation carriers","volume":"5","author":"Potter","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.arr.2023.102112_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102200","article-title":"Role of HSV-1 in Alzheimer's disease pathogenesis: a challenge for novel preventive\/therapeutic strategies","volume":"63","author":"Protto","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"issue":"19","key":"10.1016\/j.arr.2023.102112_bib19","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1016\/j.cell.2021.08.013","article-title":"The expanding amyloid family: Structure, stability, function, and pathogenesis","volume":"184","author":"Sawaya","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.arr.2023.102112_bib20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1212\/WNL.0b013e31825fdf18","article-title":"Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers","volume":"79","author":"Sch\u00f6ll","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.arr.2023.102112_bib21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects","volume":"65","author":"Shaw","year":"2009","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.arr.2023.102112_bib22","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1073\/pnas.94.8.4109","article-title":"Disaggregation of Alzheimer beta-amyloid by site-directed mAb","volume":"94","author":"Solomon","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.arr.2023.102112_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamaneurol.2020.4857","article-title":"Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical alzheimer disease: a truncated randomized phase 2b\/3 clinical trial","volume":"78","author":"Sperling","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2023.102112_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100988","article-title":"High cerebrospinal amyloid-\u03b2 42 is associated with normal cognition in individuals with brain amyloidosis","author":"Sturchio","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.arr.2023.102112_bib25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3233\/JAD-220808","article-title":"High soluble amyloid-\u03b242 predicts normal cognition in amyloid-positive individuals with alzheimer's disease-causing mutations","volume":"90","author":"Sturchio","year":"2022","journal-title":"J. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.arr.2023.102112_bib26","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1618657114","article-title":"Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A\u03b242 and A\u03b240 peptides by \u03b3-secretase","volume":"114","author":"Sun","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.arr.2023.102112_bib27","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024539","article-title":"Genetics of \u03b2-amyloid precursor protein in alzheimer's disease","volume":"7","author":"Tcw","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"4","key":"10.1016\/j.arr.2023.102112_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041413","article-title":"APP Osaka mutation in familial alzheimer's disease-its discovery, phenotypes, and mechanism of recessive inheritance","volume":"21","author":"Tomiyama","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.arr.2023.102112_bib29","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","article-title":"A beta oligomers - a decade of discovery","volume":"101","author":"Walsh","year":"2007","journal-title":"J. Neurochem."},{"issue":"4897","key":"10.1016\/j.arr.2023.102112_bib30","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1126\/science.2928783","article-title":"Amyloid beta protein enhances the survival of hippocampal neurons in vitro","volume":"243","author":"Whitson","year":"1989","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.arr.2023.102112_bib31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0304-3940(90)90867-9","article-title":"Beta-amyloid protein promotes neuritic branching in hippocampal cultures","volume":"110","author":"Whitson","year":"1990","journal-title":"Neurosci. Lett."},{"issue":"667","key":"10.1016\/j.arr.2023.102112_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn9380","article-title":"Synaptogenic effect of APP-Swedish mutation in familial Alzheimer's disease","volume":"14","author":"Zhou","year":"2022","journal-title":"Sci. Transl. Med."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163723002714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163723002714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:15:16Z","timestamp":1761592516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163723002714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":32,"alternative-id":["S1568163723002714"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2023.102112","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The proteinopenia hypothesis: Loss of A\u03b242 and the onset of Alzheimer\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2023.102112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102112"}}